SGLT2 inhibitors may improve glycaemic control and renal markers without affecting body weight in patients with Prader-Willi syndrome and T2D, but they are tied to an elevated risk for adverse events.
Multidisciplinary care that includes growth hormone treatment should not cease once patients with Prader-Willi syndrome reach adulthood, according to authors of a study on care outcomes. There is a ...
Findings showed DCCR significantly improved hyperphagia in patients with severe hyperphagia at baseline. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
The FDA granted orphan drug designation to an investigational drug for the treatment of Prader-Willi syndrome, according to an industry press release. Tesomet (Saniona) is an investigational, ...
Children with Prader–Willi syndrome (PWS) receive growth-hormone (GH) replacement therapy. Small studies suggested that GH administration might also benefit adults with PWS; however, GH has multiple ...
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with ...
A Prescription Drug User Fee Act target date of December 27, 2024 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
TipRanks on MSN
Soleno shares jump following competitor Acadia’s trial miss
Shares of Acadia Pharmaceuticals (ACAD) are sliding on Wednesday after the company’s Phase 3 failure in Prader-Willi syndrome. The news sent Soleno Therapeutics’ (SLNO) stock higher, with Wells Fargo ...
Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS ...
MedPage Today on MSN
Once-Monthly GLP-1 Shot? Mangos for Blood Sugar Control; New Acromegaly Treatment
The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of ...
How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...
Advances TNX-2900 For Prader-Willi Syndrome Into Phase 2 Trial. Tonix Pharmaceuticals (NASDAQ: TNXP) announced that the FDA has cleared its Investigational New Drug application to begin a Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback